期刊文献+

应用Bayesian反馈法预测老年患者头孢唑啉的药动学参数 被引量:2

Bayesian forecasting of cefazolin pharmacokinetics in elderly
下载PDF
导出
摘要 目的 应用Bayesian反馈法预测头孢唑啉在老年患者体内的药动学参数及血药浓度。方法 用HPLC测定头孢唑啉血药浓度。以 1,2个实测血药浓度作为反馈 ,用Bayesian反馈法拟合估算老年患者的个体药动学参数 ,并与非老年患者比较。结果 老年组 10例的CL为 (6 0 .1± 17.3)mL·h-1·kg-1,Vd 为 (0 .2 1± 0 .0 7)L·kg-1,t1/ 2 为 (2 .6± 0 .8)h ;非老年组 10例分别为CL(87.6± 34 .4)mL·h-1·kg-1,Vd(0 .19± 0 .0 8)L·kg-1和t1/ 2 (1.5± 0 .4)h。二组CL ,t1/ 2 之间的差异有显著意义 (P <0 .0 5 ) ,Vd之间差异则无显著意义 (P >0 .0 5 )。血药浓度预测值与实测值有良好的相关性 (r=0 .997)。结论 老年患者随增龄CL降低 ,t1/ 2 延长 ,而Vd不变。 OBJECTIVE: To forecast the individual pharmacokinetic parameters of cefazolin in elderly patients with infecton by Bayesian approach. METHODS: The cefazolin concentration in serum was measured by HPLC. Using 1 or 2 measured drug concentrations, the individual pharmacokinetic parameters were estimated by Bayesian feedback method, and then compared with those of non-elderly patients. RESULTS: The pharmacokinetic parameters in 10 elderly and 10 non-elderly were CL(60.1 ± 17.3), (87.6 ± 34.4) mL &middot h-1 &middot kg-1, Vd(0.21 ± 0.07), (0.19 ± 0.08) L &middot kg-1, t1/2 (2.6 ± 0.8), (1.5 ± 0.4) h, respectively. There was significant difference in CL and t1/2 parameters between the two groups (P d parameter (P > 0.05). CONCLUSION: The pharmacokinetic parameters estimated by Bayesian approach was similar compared with the parameters eatimated by traditional method. It is suitable for forecasting plasma concentration and optimizing individualizing dosage regimens.
出处 《中国药学杂志》 EI CAS CSCD 北大核心 2001年第7期465-467,共3页 Chinese Pharmaceutical Journal
关键词 头孢唑啉 BAYESIAN反馈法 药动学 老年人 血药浓度 Drug dosage Forecasting Optimization Patient monitoring Pharmacokinetics
  • 相关文献

参考文献6

二级参考文献15

共引文献50

同被引文献15

  • 1MacgGowan A P, Bawker K E, Wootton M, et al. Activity of moxifloxacin administered once a day against Streptococcus pneumoniae in an in vitro pharmacodynamic model of infection [J]. Antimicrob Agents Chemother, 1999,43:1560. 被引量:1
  • 2Chow A T, Fowler C, Williams R R, et al. Safety and pharmacokinetics of multiple 750 mg dose of intravenous levofloxacin in healthy volunteers [J]. Antimicrob Agents C hemother , 2 001, 4 5 ( 7 ) :2122. 被引量:1
  • 3Turnidge J. Pharmacokinitics and pharmacodynamics of fluoroquinolones [J]. Drugs, 1999,58(Suppl 2) : 29. 被引量:1
  • 4Lister P D, Sanders C C. Pharmacodynamics of levofloxacin and ciprofloxacin against Streptococcus pneumoniae [J]. J Antimicrob Chemother , 1999 , 43: 79. 被引量:1
  • 5Lacey MK, Lu W, Xu X, et al. Pharmacodynamic compareison of levofloxacin ciprofloxacin and amipicillin against Streptococcus pneumoniae in vivo and in vitro model of infection [J]. Antimicrob Agents Chemother1997,43:672. 被引量:1
  • 6Nightinale C H, Grant E M, Quintilliani R. Pharmacokinetics and pharmacodynamics of levofloxacin [J].Chemotherapy, 2000,46 (Suppl 1 ) : 6. 被引量:1
  • 7Zinner S H, Simmons K, Gilbert B. Comparative activities of ciprofloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro dynamic model [J]. Antimicrob Agents Chemother , 2000,44:773. 被引量:1
  • 8Pickerill K E, Pelladino J A, Schentag J J. Comparison of fluoroquinolones based on pharmacokinetic/pharmacodynamic parameters [J]. Pharmacotherapy, 2000,20 : 417. 被引量:1
  • 9Zhanel G G, Karlowsky J A, Palatnick L, et al. Prevalence of antibiotic resistance in respiratory tract isolates of Streptococcus pneumoniae: results of a Canadian national surveillance study [J]. Antimicrob Agents Chemother 1999,43: 2504. 被引量:1
  • 10Doern G, Pfaller M A, Kugler K. Prevalence of antibiotic resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 results from the SENTRY antibiotic surveillance program [J]. Clin Infect Dis, 1998,27: 764. 被引量:1

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部